Chemi Nutra has been granted a new patent (United States Patent 10,869,843) for phosphatidic acid, claiming that its branded Mediator PA can increase muscle mass and strength when accompanied with resistance exercise.
Chemi Nutra (Austin, TX) has been granted a new patent (United States Patent 10,869,843) for phosphatidic acid (PA), claiming that its branded Mediator PA can increase muscle mass and strength when accompanied with resistance exercise.
The patent and its claims apply exclusively to Chemi Nutra’s specially compounded, branded PA ingredient Mediator 50P PA. This is accomplished by acting on the signaling mechanism known as the mechanistic target of rapamycin (mTOR). Resistance exercise can induce muscle hypertrophy as mechanical loads activate mTOR. PA can significantly enhance mTOR signaling when accompanied with resistance exercise via upregulation and sustaining of muscle protein synthesis, which is directly responsible for converting amino acids into new skeletal muscle.
Chemi Nutra discovered how PA can significantly influence load-induced growth of skeletal muscle by acting on the mTOR pathway, and that, when consumed orally, PA exhibited noticeable effects on muscle mass and strength gains. This was especially true when adequate amounts of protein were administered within the anabolic window of individuals engaged in resistance exercise bouts.
“Mediator Phosphatidic Acid is the ‘Original PA,’ the only PA clinically evaluated for efficacy and safety, and the only PA proven to benefit,” said Scott Hagerman, president of Chemi Nutra, in a press release. “And now it is supported by an impressive U.S. patent.”
Should any other PA or generic PA make claims regarding muscle or strength gains, this would constitute patent infringement. Chemi Nutra customers will be granted royalty-free use of this patent.